When the FDA approved zuranolone (Zurzuvae) for postpartum depression in 2023 while declining to approve it for major depressive disorder, the agency made a defensible scientific decision and an indefensible commercial one. The science was contested but reasonable — the MDD program produced modest effect sizes and one failed pivotal trial. The commercial structure that resulted has now produced exactly the outcome a more sophisticated review would have anticipated.
The structural trap
A PPD-only label creates several intersecting constraints that compound rather than offset each other.
First, the addressable patient population is small. PPD prevalence is substantial in absolute terms, but the diagnosed and pharmacologically treated population is a fraction of that. Most postpartum depression is managed by SSRIs through obstetric and primary care channels, not by psychiatry referrals.
Second, the prescribing pathway is fragmented. Obstetricians, who see PPD patients most directly, are not typically comfortable prescribing a novel neurosteroid. Psychiatrists, who would be, are not typically the first clinician a postpartum patient sees.
Third, the price point that supports an innovative drug program is incompatible with the volume that an obstetrics channel can deliver. Sage and partner Biogen priced Zurzuvae at roughly $16,000 for a 14-day course — a price the science arguably supports but the commercial structure cannot sustain on PPD volume alone.
What the company is doing about it
Sage has publicly signaled exploration of strategic alternatives. The pipeline includes additional neurosteroid programs and a SAGE-718 program in cognitive disorders, but the company’s market cap has collapsed to a level where it trades closer to its cash position than to its pipeline value.
The realistic outcomes from here narrow quickly. A strategic acquirer with broader psychiatric commercial infrastructure — Biogen itself, or a larger pharma with both psychiatry and women’s health channels — would solve the channel fragmentation problem. An acquisition would also rationalize the cost structure of a clinical-stage company carrying commercial overhead for a label that cannot support it.
The generalizable lesson
The mistake to learn from is not narrowly Sage’s. Several upcoming psychedelic and rapid-acting antidepressant programs face the same indication-versus-label question. A “go for the narrowest indication that gets approved” strategy, which has worked beautifully in oncology, does not work the same way in psychiatry. Psychiatric labels require commercial infrastructure that scales with patient volume, and the channels are not interchangeable across indications.
Sponsors mid-stream in MDD and TRD programs should be reading the Sage outcome closely. The wrong narrow-indication strategy can produce an asset that is scientifically valid and commercially trapped.